LadRx Corp (LADXD)

[surf1944]

8:34AM CytRx receives recommendation from Data Safety Monitoring Committee to complete international Phase 2b trial with Aldoxorubicin as first-line treatment for soft tissue sarcoma (CYTR) 2.68 : No significant safety issues found with delivery of doxorubicin at 3.5 times its standard dose with aldoxorubicin, the first clinical-stage oncology candidate formed with CytRx's proprietary linker technology platform This Phase 2b trial allows for a head-to-head clinical comparison of the commonly used chemotherapeutic agent doxorubicin with aldoxorubicin, CytRx's tumor-targeting doxorubicin conjugate. Doxorubicin is dose-limited at a level below its maximum anti-tumor capabilities due to toxicity, including cardiotoxicity. Data from the Phase 2b trial is expected in the second half of 2013.